Skip to content

With an Eye on the Future, Biolog Launches Odin

Biolog, Inc. 2 mins read

HAYWARD, CA / ACCESSWIRE / June 15, 2023 / Biolog, Inc., a leading provider of microbial polyphasic analysis, today announced the launch of the Odin™ system, an all-in-one cellular phenotyping and microbial identification platform. Odin is compatible with all Biolog assays and is available now.

Until today, Biolog's OmniLog® platform was the gold standard for researchers who want actionable insights on microbial metabolic phenotypes. Odin now builds on that foundation while maintaining the core capabilities to incubate, analyze, and compare thousands of microbial and mammalian growth conditions in a single experiment, and to identify aerobic bacteria by its metabolic fingerprint.

Odin changes up the detection method and uses Optical Density (OD), which enables a critical additional modality to measure cell growth. Now on a single platform, researchers can distinguish the effect of a substrate on growth (by OD) and by respiration using our proprietary dye, now an absorbance-based measurement. With the additional Odin capabilities, researchers can now decouple a microbe's respiration rate from its division rate and more fully understand the metabolic output of a cell. With a fully loaded system, Odin records the OD for all conditions for up to 50 plates at a time, measuring the kinetics of cell growth and respiration for thousands of conditions in parallel.

Odin also has broader identification capabilities, including anaerobes, yeast, and filamentous fungi. All told, Odin can identify thousands of microbes, allowing researchers to classify unknown organisms and phenotype them on the same platform.

"We heard from our customers the need to directly measure growth. In a short time, we brought in additional scientific expertise, and built a product development engine. The customer-focused mindset and our dedicated teams have enabled us to quickly meet the needs of our customers," said Robert Wicke, CEO of Biolog.

"Understanding how microbes respond to their environment and food sources is the major economic driver in sustainable agriculture, bioprocessing and synthetic biology, to name just a few areas. We are enthusiastic about the foundation that Odin creates for Biolog and our customers," said Mr. Wicke.

About Biolog

Biolog has the tools, services, and support to provide the microbial phenotypic characterization and polyphasic identification capabilities required to produce functionally relevant insights. Our products and services enable characterization of microbial and mammalian cells as well as identification of thousands of species of bacteria, yeast, and fungi. Learn more at

Contact Information:

John Proctor, Ph.D.

SOURCE: Biolog Inc.


View source version on

More from this category

  • Biotechnology, Medical Health Aged Care
  • 24/11/2023
  • 13:15
Island Pharmaceuticals

Island Pharmaceuticals doses first cohort in ISLA-101 Single Ascending Dose study

TheSingleAscendingDosestudyisadoseescalationstudy,inwhichthreecohorts ofhealthysubjectswillreceive escalatingdosesofISLA-101 Studywillensurethatadministereddosescansafelyachievebloodconcentrations of ISLA-101 that are predicted to be effective against the dengue virus Datareadoutfromthestudyisexpectedinearly2024 MELBOURNE Australia, 24 November 2023: Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; “Island”; “the Company”) is pleased to announce that it has dosed the first cohort in its Single Ascending Dose (SAD) study for ISLA-101,awell-knowndrugcandidatebeingrepurposedforthepreventionandtreatment of dengue and other mosquito (or vector) borne diseases. The Single Ascending Dose study is being run at Scientia Clinical Research’s clinical trial facilities in Sydney (NSW), Australia, by Contract Research Organisation, Beyond Drug Development (ASX: 25 September 2023). Studyresultsareexpectedinearly2024.Theinsightsgainedfromthisstudywillpavethe wayforoptimisingprotocolsforIsland’s plannedPhase2aPEACHclinicaltrial. CEO of Island…

  • Contains:
  • Biotechnology, Business Company News
  • 23/11/2023
  • 09:34

ASX Hopeful Aegros Appoints Ex-MP As Advisory Committee Chair

Australia’s leading blood fractionator announces a trio of strategic advisor appointments as it lays the groundwork for an IPO Aegros has established a Strategic Advisory Committee (SAC), to provide advice to the Board in preparation for the company’s Initial Public Offering (IPO). The high-profile SAC members will be drawn from experts in their fields, to provide the Board with strategic advice in the lead up to its IPO. This comes after the company signed an agreement with the Queensland Government to build a 1,000,000 litre facility in Springfield, southwest of Brisbane worth over $350 million. 23 November: AEGROS today cemented…

  • Contains:
  • Biotechnology
  • 21/11/2023
  • 12:22
Biostar Stem Cell Research Institute

Stem Cell Therapy Developed in Korea Begins Treatment for Parkinson’s Disease Patients Worldwide in Japan

Biostar Stem Cell Research Institute has received approval from Japan's Ministry of Health, Labor and Welfare to Treat Parkinson's Disease. The combination of intravenous and spinal cord cavity administration is expected to increase the effectiveness of the treatment. This therapy may also be effective for other incurable neurological diseases. The stem cells are cultured in special media produced by Nature Cell, an affiliate of Biostar Stem Cell Research Institute. This proprietary culture media contributes to the safety and effectivenessSEOUL, SOUTH KOREA / ACCESSWIRE / November 20, 2023 / Korea's leading adult stem cell research institute, Biostar Stem Cell Research Institute…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time your distribute with Medianet. Pay per release or save with a subscription.